Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children Under 12 Years of Age With Hyperkalaemia (EMERALD2)

NCT05766839 is registered in ClinicalTrials.gov with Vifor Pharma, Inc. as lead sponsor.

NCT NCT05766839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05766839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children Under 12 Years of Age With Hyperkalaemia (EMERALD2)
Lead sponsor
Vifor Pharma, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
April 6, 2025
Completion date
December 1, 2030
Enrollment
36 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

hyperkalemia